– USA, NY – Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced the addition of Ellen Richstone to its board of directors, bringing extensive financial and operational experience to the board.
“Ellen’s expertise leading companies and serving shareholder interests on public company boards will be a valuable addition to our organization. Her career working in operations and financial capacities across diverse industries has afforded Ellen valuable perspectives. We look forward to leveraging her experiences as we evolve our business.” said CEO, Lisa Ricciardi.
Ellen who served as CFO and treasurer for Fortune 500 companies, and as a board member for companies in the manufacturing and technology industries will join the audit committee as its chair.
About Ellen B. Richstone
Ellen Richstone currently serves on the boards of eMagin, a company developing OLED microdisplay technology for virtual and augmented reality applications; Superior Industries International, a manufacturer of cast aluminum automotive wheels; and Orion Energy Systems, a company dedicated to the manufacture of sustainable and energy-efficient LED lighting systems. Earlier in her career, she was CFO at public and private companies ranging in size up to Fortune 500, including Sonus Networks, Rohr Aerospace (Fortune 500), and Augat (former public company, now a division of TE Connectivity Ltd), in which positions she completed and integrated over 35 acquisitions and raised a combined $1 billion in equity and debt.
Mrs. Richstone graduated from Scripps College in Claremont, California, and holds a Master of Arts in international affairs and a Master of Arts in Law and Diplomacy with a specialty in international business law from the Fletcher School of Law and Diplomacy at Tufts University. In addition, she completed the Advanced Professional Certificate in Finance at New York University’s Graduate School of Business Administration. In 2020, Mrs. Richstone was named to the National Association of Corporate Directors Directorship 100 for her work in board leadership and governance; and in 2013, was given the Distinguished Director Award from the American College of Corporate Directors. She also sits on the board of the New England chapter of the National Association of Corporate Directors.
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.
For more information: https://cogrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
